Fig. 4

In vitro tumor suppressor activity of miR-22 in MM cells. a Left panel: CTG assay was performed 96 h after transfection of indicated MM cell lines with miR-22 mimics or scrambled controls (miR-NC). *p < 0.01. Right panel: cell viability of CD138+ cells from three different MM patients co-cultured with HS-5 stromal cells and transfected with miR-22 mimics or miR-NC. The assay was performed 48 h after cell transfection. *p < 0.05, **p < 0.01. b CTG assay performed in ABZB cells (left panel) and in primary PCs from n = 5 relapsed MM patients (right panel) 48 h after co-treatment with miR-22 and bortezomib. *p < 0.05; °synergistic index > 1.0. c AMO1 cells were co-transfected with LIG3 ORF or control ORF and miR-22 mimics or miR-NC: left panel: CTG survival assay were performed 96 h after transfection. *p < 0.01. Right panel: immunoblot shows the levels of LIG3 and GAPDH 48 h after cell transfection